A Toronto-based cannabis company recently announced a partnership with a multi-state operator of medical cannabis clinics.
The partnership, between Heritage Cannabis Holdings Corp.'s Endocanna Health and Omni Medical Services, will allow the companies to collaborate and study what cannabis-based plants are best for patients, a Jan. 18 press release stated.
David Schwede, CEO of Heritage Cannabis, said the partnership could lead to the production of the best strain of plant-based medicines for patients by examining their endocannabinoid system
“We are impressed with the advancements being made by Endocanna in helping medical cannabis patients discover their own unique responses to cannabinoids and terpenes,” Schwede said in the release. “The partnership between OMNI and Endocanna will help accelerate the understanding of the medical benefits of cannabis, including the exciting potential for the use of cannabis products in the treatment of and recovery for those experiencing COVID-19.”
The project will involve the assessment of metabolic function and drug to drug interactions, along with studying ideal procedures of consumption and dosing based on metabolic function, according to the release.
“Endocanna’s EndoDNA test kits analyze essential biomolecules in the human endocannabinoid system to formulate and identify the ratios of CBD and cannabis the body metabolizes most effectively," the release stated.
Heritage Cannabis provides products to the medical and recreational legal cannabis markets in the United States and Canada. The company has two licensed manufacturing facilities in Canada.